Spring direct naar de hoofdnavigatie of de inhoud
‘To explore, together with a client, how the best IP protection can be obtained is for me the logical next step after an invention has been made.’
Frits Michiels

Frits Michiels

  • Life Sciences
  • European and Dutch Patent Attorney
  • Valuation specialist
  • Partner

Frits Michiels has had an extensive scientific career in both knowledge institutes and biotech companies. From 2004, he was employed as IP manager at Galapagos Genomics BV and subsequently also at other Dutch biotech startups, such as Agendia and Merus. He has worked for V.O. since 2006.

Continue reading

He is specialized in biochemistry, molecular biology, cell biology, diagnostics, signal transduction, and medical biotechnology. His clients are primarily knowledge institutes and start ups. He is involved in patent prosecution and strategic advice.

Working experience

  • Patent Attorney, V.O. (2006-present)
  • Merus (2006)
  • Galapagos Genomics (1999-2005)
  • Senior Scientist at the Netherlands Cancer Institute (1994-1998)
  • Post-Doc, Amsterdam Medical Center (1991-1993)
  • PhD research at Max Planck Institute for Biochemistry, Munich (1985-1990)

Education

  • PhD in Genetics, Radboud University Nijmegen (1990)
  • MSc in Microbiology, Radboud University Nijmegen (1984)

Publications

  • Michiels, GAM Damages extended to after termination of a tort. MIP Vol 205: 94-95 (2011)
  • JP ten Klooster, EE Evers, L Janssen, LM Machesky, F Michiels, P Hordijk and JG Collard. Biochem J. 397, 39–45 (2006)
  • GJ Arts, E Langemeijer, R Tissingh, L Ma, H Pavliska, K Dokic, R Dooijes, E Mesić, R Clasen, F Michiels, J van der Schueren, M Lambrecht, S Herman, R Brys, K Thys, M Hoffmann, P Tomme, H van Es. Genome Res 13, 2325-32 (2003)
  • A Malliri, RA van der Kammen, K Clark, M van der Valk, F Michiels & JG Collard. Nature 417, 867-871 (2002)
  • F Michiels et al. Nature Biotech 20, 1154-1157 (2002)
  • R Engers, E Springer, F Michiels, JG Collard, HE Gabbert. J Biol Chem 276, 41889-97 (2001)
  • WO2002057463 Swap/counter selection; a rapid cloning
  • WO2002070744 Adenoviral library assay for E2F regulatory genes and methods and compositions for screening compounds method
  • WO2005124342 Methods and means for treatment of osteoarthritis

Languages

  • English
  • Dutch
  • German

Also see these experts

Blijke Kroezen

Blijke Kroezen

  • European and Dutch Patent Attorney, European Patent Litigator
  • Senior Associate
More experts

News

UPC Court of Appeal on “same parties” under Article 33(4) UPCA, late claim amendments, and an inventive-step framework: Meril v Edwards (EP 3 646 825)

In its decision of 25 November 2025 concerning EP 3 646 825, the Unified Patent Court (UPC) Court of Appeal addressed procedural coordination between infringement and revocation tracks, the admissibility of sequential amendment requests, and core principles for claim construction and inventive step.Continue reading

Award from Managing IP

On 1 May 1, the British magazine Managing IP once again presented its annual awards in London to IP firms worldwide for their achievements in the field of intellectual property.Continue reading

Herman Witmans and Leo Jessen retire from V.O.

Today, partners Herman Witmans and Leo Jessen retire. This marks the end of impressive careers in which they dedicated themselves with great commitment for 36 and 34 years respectively to clients, colleagues, and the development of the patent attorney profession.Continue reading

Events

AI & IP – Building an IP Strategy for AI Innovation

Keizersberg, Leuven, Belgium

V.O. Patents & Trademarks will take part in Leuven MindGate’s Deep Dive session, AI & IP - Building an IP Strategy for AI Innovation, on 4 June 2026 in Leuven.

Continue reading